High Loading Dose of Atorvastatin for the Prevention of Serum Creatinine and Cystatin C-Based Contrast-Induced Nephropathy Following Percutaneous Coronary Intervention

Abstract

The aim of this study is to assess the efficacy of high-dose atorvastatin on the prevention of contrast-induced nephropathy (CIN) in patients with acute coronary syndrome (ACS) undergoing percutaneous intervention and observe the incidence of cystatin C (CyC)-based CIN. A total of 496 patients with ACS were randomly assigned to either the control group (247 patients receiving conventional dose atorvastatin 10 mg daily from 1 day before to 3 days after contrast administration) or the high-dose atorvastatin group (249 patients receiving atorvastatin 40 mg daily for the same perioperative period). The baseline characteristics of the 2 groups were similar. The primary end point of serum creatinine (SCr)-based CIN occurred in 31 patients in the control group and 16 patients in the high-dose atorvastatin group (12.6% vs 6.4%; P = .02). Cystatin C–based CIN developed in 90 patients in the control group and 46 patients in the high-dose atorvastatin group (36.4% vs 18.5%; P < .001). A multivariable analysis revealed that high-dose atorvastatin was independently associated with a decreased risk of CIN. Our study demonstrated that prophylactic treatment with high-dose atorvastatin reduced the risk of both SCr and CyC-based CIN and suggested that CyC was a more reliable marker for early diagnosis of CIN compared with SCr.

Keywords

contrast-induced nephropathy atorvastatin cystatin C

Get full access to this article

View all access options for this article.

References

Andreucci

Faga

Pisani

Sabbatini

Michael

. Acute kidney injury by radiographic contrast media: pathogenesis and prevention. Biomed Res Int. 2014;2014:362725.

Quintavalle

Fiore

De Micco

. Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury. Circulation. 2012;126(25):3008–16.

Shehata

Hamza

. Impact of high loading dose of atorvastatin in diabetic patients with renal dysfunction undergoing elective percutaneous coronary intervention: a randomized controlled trial. Cardiovasc Ther. 2015;33(2):35–41.

Toso

Maioli

Leoncini

. Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease. Am J Cardiol. 2010;105(3):288–92.

Bellomo

Kellum

Ronco

. Defining acute renal failure: physiological principles. Intensive Care Med. 2004;30(1):33–7.

Paragas

Qiu

Zhang

. The NGAL reporter mouse detects the response of the kidney to injury in real time. Nat Med. 2011;17(2):216–22.

Duan

Liu

. Urinary KIM-1, IL-18 and Cys-c as early predictive biomarkers in gadolinium-based contrast-induced nephropathy in the elderly patients. Clin Nephrol. 2013;80(5):349–54.

Gowda

Desai

Kulkarni

Hull

Math

Vernekar

. Markers of renal function tests. N Am J Med Sci. 2010;2(4):170–3.

Smith

Jr Feldman

Hirshfeld

Jr . ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation. 2006;113(7):e166–e286.

10.

Levey

Coresh

Greene

. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247–54.

11.

Budano

Levis

D’Amico

. Impact of contrast-induced acute kidney injury definition on clinical outcomes. Am Heart J. 2011;161(5):963–71.

12.

Briguori

Visconti

Rivera

. Cystatin C and contrast-induced acute kidney injury. Circulation. 2010;121(19):2117–22.

13.

Thygesen

Alpert

Jaffe

; Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction . Third universal definition of myocardial infarction. Circulation. 2012;126(16):2020–35.

14.

Laskey

Jenkins

Selzer

; NHLBI Dynamic Registry Investigators. Volume-to-creatinine clearance ratio: a pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention. J Am Coll Cardiol. 2007;50(7):584–90.

15.

Mehran

Aymong

Nikolsky

. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44(7):1393–9.

16.

Padhy

Kaushik

Girish

Mohapatra

Shah

Koner

. Serum neutrophil gelatinase associated lipocalin (NGAL) and cystatin C as early predictors of contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention. Clin Chim Acta. 2014;435:48–52.

17.

Yin

Liu

. Probucol for the prevention of cystatin C-based contrast-induced acute kidney injury following primary or urgent angioplasty: a randomized, controlled trial. Int J Cardiol. 2013;167(2):426–9.

18.

Wang

Zhang

. Comparison of effects of different statins on contrast-induced acute kidney injury in rats: histopathological and biochemical findings. Oxid Med Cell Longev. 2017;2017:6282486.

19.

Tan

. Atorvastatin attenuates contrast-induced nephropathy by modulating inflammatory responses through the regulation of JNK/p38/Hsp27 expression. J Pharmacol Sci. 2016;131(1):18–27.

20.

Hudzik

Szkodzinski

Danikiewicz

. Serum interleukin-6 concentration predicts contrast-induced nephropathy in patients undergoing percutaneous coronary intervention. Eur Cytokine Netw. 2010;21(2):129–35.

21.

Wassmann

Laufs

Muller

. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol. 2002;22(2):300–5.

22.

Wong

Guo

Zhang

. Pathophysiology of contrast-induced nephropathy. Int J Cardiol. 2012;158(2):186–92.

23.

Karaman

Diyarbakir

Durur-Subasi

. A novel approach to contrast-induced nephrotoxicity: the melatonergic agent agomelatine. Br J Radiol. 2016;89(1061):20150716.

24.

Kunak

Ugan

Cadirci

. Nephroprotective potential of carnitine against glycerol and contrast-induced kidney injury in rats through modulation of oxidative stress, proinflammatory cytokines, and apoptosis. Br J Radiol. 2016;89(1058):20140724.

25.

Zou

Cai

. Atorvastatin ameliorates contrast medium-induced renal tubular cell apoptosis in diabetic rats via suppression of Rho-kinase pathway. Eur J Pharmacol. 2014;723:15–22.

26.

Dai

. High dose of atorvastatin for the treatment of contrast-induced nephropathy after carotid artery stenting. Am J Ther. 2017;24(6):e718–22.

27.

Abaci

Harmankaya

Kocas

. Long-term follow-up of patients at high risk for nephropathy after contrast exposure. Angiology. 2015;66(6):514–8.

28.

Uzunhasan

Yildiz

Arslan

. Contrast-induced acute kidney injury is associated with long-term adverse events in patients with acute coronary syndrome. Angiology. 2017;68(7):621–26.